{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:29:13Z","timestamp":1786663753440,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Human Life CORD Japan Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56402-y","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:45:21Z","timestamp":1780508721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Soluble PD-L1-secreting umbilical cord-derived mesenchymal stromal cells transiently attenuate established xenogeneic T cell activation in vivo"],"prefix":"10.1038","volume":"16","author":[{"given":"Ryosuke","family":"Uchibori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiya","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"56402_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4252\/wjsc.v6.i2.195","volume":"6","author":"T Nagamura-Inoue","year":"2014","unstructured":"Nagamura-Inoue, T. & He, H. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J. Stem Cells 6, 195\u2013202 (2014).","journal-title":"World J. Stem Cells"},{"key":"56402_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.bbrc.2014.03.051","volume":"446","author":"M Lee","year":"2014","unstructured":"Lee, M. et al. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 446, 983\u2013989 (2014).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"56402_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6901286","volume":"2016","author":"I Arutyunyan","year":"2016","unstructured":"Arutyunyan, I., Elchaninov, A., Makarov, A. & Fatkhudinov, T. Umbilical cord as prospective source for mesenchymal stem cell-based therapy. Stem Cells Int. 2016, 6901286. https:\/\/doi.org\/10.1155\/2016\/6901286 (2016).","journal-title":"Stem Cells Int."},{"key":"56402_CR4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau, J. & Senseb\u00e9, L. Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities. Cell Stem Cell 22, 824\u2013833 (2018).","journal-title":"Cell Stem Cell"},{"key":"56402_CR5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/cr.2010.44","volume":"20","author":"Y Shi","year":"2010","unstructured":"Shi, Y. et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res. 20, 510\u2013518 (2010).","journal-title":"Cell Res."},{"key":"56402_CR6","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui, E. et al. T cell costimulatory receptor CD28 is a primary target for PD-1\u2013mediated inhibition. Science 355, 1428\u20131433 (2017).","journal-title":"Science"},{"key":"56402_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01597","volume":"8","author":"ZY Xu-Monette","year":"2017","unstructured":"Xu-Monette, Z. Y., Zhang, M., Li, J. & Young, K. H. PD-1\/PD-L1 blockade: Have we found the key to unleash the antitumor immune response?. Front. Immunol. 8, 1597. https:\/\/doi.org\/10.3389\/fimmu.2017.01597 (2017).","journal-title":"Front. Immunol."},{"key":"56402_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677\u2013704 (2008).","journal-title":"Annu. Rev. Immunol."},{"key":"56402_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179531","volume":"22","author":"L L\u00f3pez-Garc\u00eda","year":"2021","unstructured":"L\u00f3pez-Garc\u00eda, L. & Castro-Manrreza, M. E. TNF-alpha and IFN-gamma participate in improving the immunoregulatory capacity of mesenchymal stem\/stromal cells: Importance of cell-cell contact and extracellular vesicles. Int. J. Mol. Sci. 22, 9531 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"56402_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2007.11.014","volume":"2","author":"G Ren","year":"2008","unstructured":"Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141\u2013150 (2008).","journal-title":"Cell Stem Cell"},{"key":"56402_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1074863","volume":"14","author":"W Li","year":"2023","unstructured":"Li, W. et al. The role of TNF-\u03b1 in the fate regulation and functional reprogramming of mesenchymal stem cells in an inflammatory microenvironment. Front. Immunol. 14, 1074863. https:\/\/doi.org\/10.3389\/fimmu.2023.1074863 (2023).","journal-title":"Front. Immunol."},{"key":"56402_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4252\/wjsc.v15.i8.787","volume":"15","author":"Z Chen","year":"2023","unstructured":"Chen, Z. et al. Interferon-gamma and tumor necrosis factor-alpha synergistically enhance the immunosuppressive capacity of human umbilical-cord-derived mesenchymal stem cells by increasing PD-L1 expression. World J. Stem Cells 15, 787\u2013806 (2023).","journal-title":"World J. Stem Cells"},{"key":"56402_CR13","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","volume":"105","author":"S Aggarwal","year":"2005","unstructured":"Aggarwal, S. & Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815\u20131822 (2005).","journal-title":"Blood"},{"key":"56402_CR14","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1182\/blood-2003-11-3909","volume":"103","author":"R Meisel","year":"2004","unstructured":"Meisel, R. et al. Human bone marrow stromal cells inhibit allogeneic T cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103, 4619\u20134621 (2004).","journal-title":"Blood"},{"key":"56402_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nm.1905","volume":"15","author":"K N\u00e9meth","year":"2009","unstructured":"N\u00e9meth, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15, 42\u201349 (2009).","journal-title":"Nat. Med."},{"key":"56402_CR16","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1097\/TP.0b013e3181a2a4b3","volume":"87","author":"Z Selmani","year":"2009","unstructured":"Selmani, Z. et al. HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 87, S62\u2013S66 (2009).","journal-title":"Transplantation"},{"key":"56402_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jcyt.2015.10.011","volume":"18","author":"M Najar","year":"2016","unstructured":"Najar, M. et al. Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells. Cytotherapy 18, 160\u2013171 (2016).","journal-title":"Cytotherapy"},{"key":"56402_CR18","doi-asserted-by":"publisher","first-page":"88360","DOI":"10.18632\/oncotarget.21729","volume":"8","author":"Z Liang","year":"2017","unstructured":"Liang, Z. et al. High-affinity human PD-L1 variants attenuate the suppression of T cell activation. Oncotarget 8, 88360\u201388375 (2017).","journal-title":"Oncotarget"},{"key":"56402_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133883","volume":"14","author":"Z Liang","year":"2023","unstructured":"Liang, Z. et al. Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells. Front. Immunol. 14, 1133883. https:\/\/doi.org\/10.3389\/fimmu.2023.1133883 (2023).","journal-title":"Front. Immunol."},{"key":"56402_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00297","volume":"3","author":"E Eggenhofer","year":"2012","unstructured":"Eggenhofer, E. et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front. Immunol. 3, 297. https:\/\/doi.org\/10.3389\/fimmu.2012.00297 (2012).","journal-title":"Front. Immunol."},{"key":"56402_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.709225","volume":"9","author":"E Ferrini","year":"2021","unstructured":"Ferrini, E. et al. Persistency of mesenchymal stromal\/stem cells in lungs. Front. Cell Dev. Biol. 9, 709225. https:\/\/doi.org\/10.3389\/fcell.2021.709225 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"56402_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.omto.2018.11.003","volume":"12","author":"R Uchibori","year":"2018","unstructured":"Uchibori, R. et al. Functional analysis of an inducible promoter driven by activation signals from a chimeric antigen receptor. Mol. Ther. Oncolytics 12, 16\u201325 (2018).","journal-title":"Mol. Ther. Oncolytics"},{"key":"56402_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/cdd.2013.158","volume":"21","author":"S Ma","year":"2014","unstructured":"Ma, S. et al. Immunobiology of mesenchymal stem cells. Cell Death Differ. 21, 216\u2013225. https:\/\/doi.org\/10.1038\/cdd.2013.158 (2014).","journal-title":"Cell Death Differ."},{"key":"56402_CR24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli, A., Moretta, L. & Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8, 726\u2013736. https:\/\/doi.org\/10.1038\/nri2395 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"56402_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.imlet.2015.05.004","volume":"168","author":"K Le Blanc","year":"2015","unstructured":"Le Blanc, K. & Davies, L. C. Mesenchymal stromal cells and the innate immune response.. Immunol. Lett. 168, 140\u2013146. https:\/\/doi.org\/10.1016\/j.imlet.2015.05.004 (2015).","journal-title":"Immunol. Lett."},{"key":"56402_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2492\/inflammregen.35.233","volume":"35","author":"Y Matsuzaki","year":"2015","unstructured":"Matsuzaki, Y. Immunomodulation of mesenchymal stem\/stromal cells for the onset of cGVHD. Inflamm. Regen. 35, 233\u2013237. https:\/\/doi.org\/10.2492\/inflammregen.35.233 (2015).","journal-title":"Inflamm. Regen."},{"key":"56402_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199436","volume":"26","author":"P Mallis","year":"2025","unstructured":"Mallis, P. et al. The impact of IFN-\u03b3 licensing on mesenchymal stromal cells\u2019 mediated immunoregulation and HLA class II expression: Emerging evidence from in vitro results. Int. J. Mol. Sci. 26, 9436. https:\/\/doi.org\/10.3390\/ijms26199436 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"56402_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bmt.1705644","volume":"39","author":"CK Min","year":"2007","unstructured":"Min, C. K., Kim, B. G., Park, G., Cho, B. & Oh, I. H. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant. 39, 637\u2013645. https:\/\/doi.org\/10.1038\/sj.bmt.1705644 (2007).","journal-title":"Bone Marrow Transplant."},{"key":"56402_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cjtee.2023.11.003","volume":"27","author":"Z Chen","year":"2024","unstructured":"Chen, Z. et al. The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells. Chin. J. Traumatol. 27, 1\u201310. https:\/\/doi.org\/10.1016\/j.cjtee.2023.11.003 (2024).","journal-title":"Chin. J. Traumatol."},{"key":"56402_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00580-2","volume":"12","author":"A Hazrati","year":"2024","unstructured":"Hazrati, A., Malekpour, K., Khorramdelazad, H., Rajaei, S. & Hashemi, S. M. Therapeutic and immunomodulatory potentials of mesenchymal stromal\/stem cells and immune checkpoints related molecules. Biomark. Res. 12, 35. https:\/\/doi.org\/10.1186\/s40364-024-00580-2 (2024).","journal-title":"Biomark. Res."},{"key":"56402_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-00431-1","volume":"10","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. Interleukin-17 promotes nitric oxide-dependent expression of PD-L1 in mesenchymal stem cells. Cell Biosci. 10, 73. https:\/\/doi.org\/10.1186\/s13578-020-00431-1 (2020).","journal-title":"Cell Biosci."},{"key":"56402_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04822-9","volume":"13","author":"Y He","year":"2022","unstructured":"He, Y. et al. Mesenchymal stem cells empower T cells in the lymph nodes via MCP-1\/PD-L1 axis. Cell Death Dis. 13, 365. https:\/\/doi.org\/10.1038\/s41419-022-04822-9 (2022).","journal-title":"Cell Death Dis."},{"key":"56402_CR33","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1073\/pnas.0812851107","volume":"107","author":"D Busse","year":"2010","unstructured":"Busse, D. et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc. Natl. Acad. Sci. U. S. A. 107, 3058\u20133063. https:\/\/doi.org\/10.1073\/pnas.0812851107 (2010).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"56402_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","volume":"38","author":"W Liao","year":"2013","unstructured":"Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13\u201325. https:\/\/doi.org\/10.1016\/j.immuni.2013.01.004 (2013).","journal-title":"Immunity"},{"key":"56402_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.100249","volume":"19","author":"M Thompson","year":"2020","unstructured":"Thompson, M. et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine 19, 100249. https:\/\/doi.org\/10.1016\/j.eclinm.2019.100249 (2020).","journal-title":"EClinicalMedicine"},{"key":"56402_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01193-z","volume":"20","author":"X Zhou","year":"2020","unstructured":"Zhou, X., Jin, N., Wang, F. & Chen, B. Mesenchymal stem cells: A promising way in therapies of graft-versus-host disease. Cancer Cell Int. 20, 114. https:\/\/doi.org\/10.1186\/s12935-020-01193-z (2020).","journal-title":"Cancer Cell Int."},{"key":"56402_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00684-9","volume":"12","author":"G Ehx","year":"2024","unstructured":"Ehx, G., Ritacco, C. & Baron, F. Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice. Biomark. Res. 12, 139. https:\/\/doi.org\/10.1186\/s40364-024-00684-9 (2024).","journal-title":"Biomark. Res."},{"key":"56402_CR38","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/cei.12180","volume":"174","author":"L Covassin","year":"2013","unstructured":"Covassin, L. et al. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2r\u03b3(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells. Clin. Exp. Immunol. 174, 372\u2013388. https:\/\/doi.org\/10.1111\/cei.12180 (2013).","journal-title":"Clin. Exp. Immunol."},{"key":"56402_CR39","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.21873\/anticanres.14540","volume":"40","author":"YM Morillon 2nd","year":"2020","unstructured":"Morillon, Y. M. 2nd., Sabzevari, A., Schlom, J. & Greiner, J. W. The development of next-generation PBMC humanized mice for preclinical investigation of cancer immunotherapeutic agents. Anticancer Res. 40, 5329\u20135341. https:\/\/doi.org\/10.21873\/anticanres.14540 (2020).","journal-title":"Anticancer Res."},{"key":"56402_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50256","volume":"8","author":"KW Ng","year":"2019","unstructured":"Ng, K. W. et al. Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. Elife 8, e50256. https:\/\/doi.org\/10.7554\/eLife.50256 (2019).","journal-title":"Elife"},{"key":"56402_CR41","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1097\/01.tp.0000250757.69384.79","volume":"82","author":"J Dudler","year":"2006","unstructured":"Dudler, J. et al. Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival. Transplantation 82, 1733\u20131737. https:\/\/doi.org\/10.1097\/01.tp.0000250757.69384.79 (2006).","journal-title":"Transplantation"},{"key":"56402_CR42","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.2337\/db07-1260","volume":"57","author":"CJ Wang","year":"2008","unstructured":"Wang, C. J. et al. Protective role of programmed death 1 ligand 1 (PD-L1) in nonobese diabetic mice: the paradox in transgenic models. Diabetes 57, 1861\u20131869. https:\/\/doi.org\/10.2337\/db07-1260 (2008).","journal-title":"Diabetes"},{"key":"56402_CR43","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/j.1432-2277.2010.01130.x","volume":"23","author":"A Plege","year":"2010","unstructured":"Plege, A. et al. Downregulation of cytolytic activity of human effector cells by transgenic expression of human PD-ligand-1 on porcine target cells. Transpl. Int. 23, 1293\u20131300. https:\/\/doi.org\/10.1111\/j.1432-2277.2010.01130.x (2010).","journal-title":"Transpl. Int."},{"key":"56402_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113101","volume":"10","author":"C Zhang","year":"2021","unstructured":"Zhang, C. et al. IL-10 mRNA engineered MSCs demonstrate enhanced anti-inflammation in an acute GvHD model. Cells 10, 3101. https:\/\/doi.org\/10.3390\/cells10113101 (2021).","journal-title":"Cells"},{"key":"56402_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010534","volume":"23","author":"AM Vacaru","year":"2022","unstructured":"Vacaru, A. M. et al. Treatment with mesenchymal stromal cells overexpressing Fas-Ligand ameliorates acute Graft-versus-Host Disease in mice. Int. J. Mol. Sci. 23, 534. https:\/\/doi.org\/10.3390\/ijms23010534 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"56402_CR46","doi-asserted-by":"publisher","first-page":"1062086","DOI":"10.3389\/fimmu.2023.1062086","volume":"14","author":"R Herv\u00e1s-Salcedo","year":"2023","unstructured":"Herv\u00e1s-Salcedo, R. et al. Improved efficacy of mesenchymal stromal cells stably expressing CXCR4 and IL-10 in a xenogeneic graft versus host disease mouse model. Front. Immunol. 14, 1062086. https:\/\/doi.org\/10.3389\/fimmu.2023.1062086 (2023).","journal-title":"Front. Immunol."},{"key":"56402_CR47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12185-015-1930-x","volume":"103","author":"K Miyamura","year":"2016","unstructured":"Miyamura, K. Insurance approval of mesenchymal stem cell for acute GVHD in Japan: Need of follow up for some remaining concerns. Int. J. Hematol. 103, 155\u2013164. https:\/\/doi.org\/10.1007\/s12185-015-1930-x (2016).","journal-title":"Int. J. Hematol."},{"key":"56402_CR48","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.bbmt.2020.02.023","volume":"26","author":"J Galipeau","year":"2020","unstructured":"Galipeau, J. Mesenchymal stromal cells for graft-versus-host disease: A trilogy. Biol. Blood Marrow Transpl. 26, e89\u2013e91. https:\/\/doi.org\/10.1016\/j.bbmt.2020.02.023 (2020).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"56402_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jama.2025.6179","volume":"334","author":"U Mahat","year":"2025","unstructured":"Mahat, U., Przepiorka, D. & Fashoyin-Aje, L. A. Remestemcel-L-rknd for steroid-refractory acute Graft-vs-Host Disease in pediatric patients. JAMA 334, 81\u201382. https:\/\/doi.org\/10.1001\/jama.2025.6179 (2025).","journal-title":"JAMA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56402-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56402-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56402-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:17:01Z","timestamp":1786663021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56402-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56402"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56402-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RU, K Ohmine, and K Ozawa received support for research funding, editing a draft, and article processing charges from Human Life CORD Japan Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Author information<\/b>"}},{"value":"All procedures involving human umbilical cord-derived mesenchymal stromal cells (UC-MSCs) were approved by the Institutional Review Board (approval No. 23\u2013110). The collection and use of PBMCs from healthy donors were reviewed and approved by the Ethics Committee of Jichi Medical University (approval No. 22\u2013050), and written informed consent was obtained from all donors in accordance with the Declaration of Helsinki. All animal experiments were approved by the Animal Care and Use Committee of Jichi Medical University (approval Nos. 20117-01 and 24033-01) and were performed in accordance with institutional guidelines. All animal experiments were reported in accordance with the ARRIVE guidelines (\n                      \n                      ).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"<b>Author information<\/b>"}}],"article-number":"25376"}}